Stockreport

Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer [Yahoo! Finance]

ORION CORP NEW UNSP/ADR  (ORINY) 
PDF "Simply put, our ambition is to help more patients with prostate cancer," said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization a [Read more]